-
Je něco špatně v tomto záznamu ?
IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy
V. Niederlova, O. Tsyklauri, M. Kovar, O. Stepanek
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy, práce podpořená grantem
PubMed
37827864
DOI
10.1016/j.it.2023.09.003
Knihovny.cz E-zdroje
- MeSH
- CD8-pozitivní T-lymfocyty * MeSH
- cytotoxické T-lymfocyty MeSH
- fenotyp MeSH
- imunoterapie MeSH
- interleukin-2 * terapeutické užití metabolismus MeSH
- myši MeSH
- regulační T-lymfocyty MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
The therapeutic potential of interleukin (IL)-2 in cancer treatment has been known for decades, yet its widespread adoption in clinical practice remains limited. Recently, chimeric proteins of an anti-PD-1 antibody and suboptimal IL-2 variants were shown to stimulate potent antitumor and antiviral immunity by inducing unique effector CD8+ T cells in mice. A similar subset of cytotoxic T cells is induced by depletion of regulatory T cells (Tregs), suggesting IL-2 sequestration as a major mechanism through which regulatory T cells suppress activated CD8+ T cells. Here, we present our view of how IL-2-based biologicals can boost the antitumor response at a cellular level, and propose that the role of Tregs following such treatments may have been previously overestimated.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000807
- 003
- CZ-PrNML
- 005
- 20240213093401.0
- 007
- ta
- 008
- 240109s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.it.2023.09.003 $2 doi
- 035 __
- $a (PubMed)37827864
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Niederlova, Veronika $u Laboratory of Adaptive Immunity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
- 245 10
- $a IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy / $c V. Niederlova, O. Tsyklauri, M. Kovar, O. Stepanek
- 520 9_
- $a The therapeutic potential of interleukin (IL)-2 in cancer treatment has been known for decades, yet its widespread adoption in clinical practice remains limited. Recently, chimeric proteins of an anti-PD-1 antibody and suboptimal IL-2 variants were shown to stimulate potent antitumor and antiviral immunity by inducing unique effector CD8+ T cells in mice. A similar subset of cytotoxic T cells is induced by depletion of regulatory T cells (Tregs), suggesting IL-2 sequestration as a major mechanism through which regulatory T cells suppress activated CD8+ T cells. Here, we present our view of how IL-2-based biologicals can boost the antitumor response at a cellular level, and propose that the role of Tregs following such treatments may have been previously overestimated.
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a CD8-pozitivní T-lymfocyty $7 D018414
- 650 12
- $a interleukin-2 $x terapeutické užití $x metabolismus $7 D007376
- 650 _2
- $a imunoterapie $7 D007167
- 650 _2
- $a cytotoxické T-lymfocyty $7 D013602
- 650 _2
- $a regulační T-lymfocyty $7 D050378
- 650 _2
- $a fenotyp $7 D010641
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Tsyklauri, Oksana $u Laboratory of Adaptive Immunity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Kovar, Marek $u Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Stepanek, Ondrej $u Laboratory of Adaptive Immunity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic. Electronic address: ondrej.stepanek@img.cas.cz
- 773 0_
- $w MED00006036 $t Trends in immunology $x 1471-4981 $g Roč. 44, č. 11 (2023), s. 890-901
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37827864 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093358 $b ABA008
- 999 __
- $a ok $b bmc $g 2049426 $s 1210501
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 44 $c 11 $d 890-901 $e 20231010 $i 1471-4981 $m Trends in immunology $n Trends Immunol $x MED00006036
- LZP __
- $a Pubmed-20240109
